Description
Product Usage Information
Mithramycin A is supplied as a lyophilized powder. For a 1 mM stock, reconstitute 1 mg of powder in 0.92 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
Mithramycin A is an antibiotic that binds the minor groove in GC-rich regions of DNA to inhibit transcription factor-DNA binding and prevent transcriptional activation (1). Mithramycin A is a specific inhibitor of specificity protein 1 (SP1), a ubiquitously expressed transcription factor that plays a role in control of cell growth and differentiation, apoptosis, and the immune response (2). Inhibition of SP1 by Mithramycin A leads to suppression of downstream targets, including proto-oncogenes and , anti-apoptotic genes and , and the pro-angiogenic gene . Mithramycin A inhibition of SP1 suppresses anti-apoptotic gene expression and induces caspase-dependent apoptosis (3). Several studies demonstrated that nanomolar concentrations of Mithramycin A could suppress tumor growth with no apparent effect on normal cell division. Mithramycin A was used therapeutically to treat testicular cancer and myeloid leukemia. Additional work suggests a possible role of Mithramycin A in treating cervical and colorectal cancer (4).
Alternate Names
A 2371; Antibiotic LA 7017; Aureolic Acid; NSC 24559; PA 144; Plicamycin
